RxDoctor Payments Data

Timothy Mikesell, DO

Neurology · Park Ridge, ILNPI 1811933757

Payments from drug & device makers

$993in general payments, 2019–2025

Across 25 payments — averaging $39.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$562
  • Biogen$150
  • Novartis$125
  • AbbVie$34
  • AstraZeneca$30
  • Teva Pharmaceuticals USA, Inc.$25
  • plus $68 from 4 others

What the payments were for

  • Consulting fees$15015%
  • Food & beverage$84385%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$993 in reported general payments places this provider in the 50th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$49,899
Medicare patients
240
Services billed
427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin14$143,621
Nurtec OdtRimegepant Sulfate19$47,687
Aimovig AutoinjectorErenumab-Aooe37$31,880
QuliptaAtogepant23$25,313
EliquisApixaban14$16,557
Emgality PenGalcanezumab-Gnlm16$16,239
Dimethyl Fumarate25$13,999
UbrelvyUbrogepant13$13,575
Eletriptan HbrEletriptan Hydrobromide25$6,790
Gabapentin96$4,582
Levetiracetam84$4,398
Diphenhydramine Hcl13$2,191
Sumatriptan Succinate74$1,936
Carbidopa-LevodopaCarbidopa/Levodopa68$1,638
Carbamazepine18$1,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$562$143,62114 claims
AbbVieQulipta, Ubrelvy$34$38,88936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 790 neurology providers in Illinois.

Other neurology in Park Ridge

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →